Akay’s curcuminoid complex shown to boost cognition and memory

18 Jan 2021 --- Akay Group’s curcuminoid-fenugreek complex, CurQfen, was shown to improve memory and concentration compared to unformulated curcumin (UC) or a placebo.

Brain function significantly improved after consuming the complex, with audio-visual reaction times also bolstered.

“A number of bioavailable formulations of curcumin are available in the market as nutraceuticals for brain health,” explains Dr. Krishnakumar, the chief research officer at Akay.

“However, systematic information about their blood-brain barrier (BBB) permeability, brain pharmacokinetics and brain bioavailability is limited. That is why the current study has been initiated with CurQfen.”

Akay's CurQfen was can reduce reaction time by 30 percent. “Surprising” results
Published in Nutritional Neuroscience, a double-blind, randomized placebo trial-tested curcumin-galactomannan (CGM) effects on 18 healthy adults aged 35 to 65.

Each participant consumed either 500 mg CGM, 500 mg UC or a placebo twice a day for thirty days.

Electroencephalogram (EEG) measurements, audio-visual reaction time tests and a working memory test were conducted at baseline and after 30 days once the trial was completed.

The results showed that supplementation of CGM resulted in a significant increase in α- and β-waves in the brain as well as a significant reduction in α/β ratio in comparison with unformulated curcumin and placebo groups.

Moreover, CGM produced a significant reduction of 30 percent in audio-reaction time in comparison with placebo and a 24 percent reduction with unformulated curcumin.

The choice-based visual-reaction time was also significantly decreased by 36 percent in CGM compared to UC and placebo, which produced 15 percent and 5 percent, respectively.

“We were surprised to see the results of the 30-day clinical trial when the software-assisted analysis of the EEG data was completed, since this is the very first time the effect of curcumin on brain waves was investigated as a proof of its BBB permeability and brain bioavailability,” says the research team.

The study was conducted at Aman Hospital and Research Centre in Gujarat, India.

Curcumin and COVID-19
The findings join a plethora of results showing the clinical benefits CGM can have on health.

Last year, a randomized trial by Akay Group discovered that CGM can significantly reduce pain associated with osteoarthritis and is more effective at doing so than glucosamine hydrochloride and chondroitin sulfate.

Another 2020 study found that a curcuminoid complex produced by Sabinsa could decrease pro-inflammatory cytokine leptins in critically ill patients with traumatic brain injury.

Edited

By Louis Gore-Langton

To contact our editorial team please email us at editorial@cnsmedia.com